Organogenesis/$ORGO
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Organogenesis
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Ticker
$ORGO
Sector
Primary listing
Employees
869
Headquarters
Website
Organogenesis Metrics
BasicAdvanced
$584M
-
-$0.16
1.71
-
Price and volume
Market cap
$584M
Beta
1.71
52-week high
$6.71
52-week low
$2.28
Average daily volume
930K
Financial strength
Current ratio
4.122
Quick ratio
3.279
Long term debt to equity
9.068
Total debt to equity
11.583
Interest coverage (TTM)
5.04%
Profitability
EBITDA (TTM)
22.53
Gross margin (TTM)
75.85%
Net profit margin (TTM)
-3.46%
Operating margin (TTM)
1.13%
Effective tax rate (TTM)
34.50%
Revenue per employee (TTM)
$530,000
Management effectiveness
Return on assets (TTM)
0.70%
Return on equity (TTM)
-4.92%
Valuation
Price to revenue (TTM)
1.306
Price to book
2.4
Price to tangible book (TTM)
2.88
Price to free cash flow (TTM)
-85.602
Free cash flow yield (TTM)
-1.17%
Free cash flow per share (TTM)
-0.054
Growth
Revenue change (TTM)
5.35%
Earnings per share change (TTM)
-493.73%
3-year revenue growth (CAGR)
-0.23%
3-year earnings per share growth (CAGR)
-36.96%
What the Analysts think about Organogenesis
Analyst ratings (Buy, Hold, Sell) for Organogenesis stock.
Bulls say / Bears say
Organogenesis reported a 27% year-over-year revenue growth in Q4 2024, reaching $126.7 million, indicating strong market demand for its products. (stocktitan.net)
The company achieved a net income of $7.7 million in Q4 2024, a significant turnaround from a $0.6 million loss in Q4 2023, showcasing improved profitability. (stocktitan.net)
Organogenesis ended 2024 with $136.2 million in cash and zero debt, providing substantial financial flexibility for future investments. (stocktitan.net)
In Q1 2025, Organogenesis reported a net loss of $18.8 million, a significant increase from the $2.1 million loss in Q1 2024, indicating financial challenges. (santelog.com)
The company experienced a 23% decline in Advanced Wound Care product revenue in Q1 2025 compared to Q1 2024, suggesting potential market or operational issues. (santelog.com)
CMS's delay in implementing local coverage determinations introduces uncertainty regarding future reimbursement policies, which could impact Organogenesis's revenue streams. (stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
Organogenesis Financial Performance
Revenues and expenses
Organogenesis Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Organogenesis stock?
Organogenesis (ORGO) has a market cap of $584M as of August 06, 2025.
What is the P/E ratio for Organogenesis stock?
The price to earnings (P/E) ratio for Organogenesis (ORGO) stock is 0 as of August 06, 2025.
Does Organogenesis stock pay dividends?
No, Organogenesis (ORGO) stock does not pay dividends to its shareholders as of August 06, 2025.
When is the next Organogenesis dividend payment date?
Organogenesis (ORGO) stock does not pay dividends to its shareholders.
What is the beta indicator for Organogenesis?
Organogenesis (ORGO) has a beta rating of 1.71. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.